A detailed history of Compagnie Lombard Odier S Cm A transactions in Novo Nordisk A S stock. As of the latest transaction made, Compagnie Lombard Odier S Cm A holds 64,545 shares of NVO stock, worth $6.78 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
64,545
Previous 63,745 1.26%
Holding current value
$6.78 Million
Previous $9.1 Million 15.53%
% of portfolio
0.13%
Previous 0.16%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$119.07 - $145.42 $95,256 - $116,335
800 Added 1.26%
64,545 $7.69 Million
Q2 2024

Jul 18, 2024

SELL
$122.71 - $146.91 $10,430 - $12,487
-85 Reduced 0.13%
63,745 $9.1 Million
Q1 2024

May 01, 2024

BUY
$102.11 - $135.92 $740,808 - $986,099
7,255 Added 12.82%
63,830 $8.2 Million
Q4 2023

Jan 16, 2024

BUY
$87.78 - $105.45 $760,613 - $913,724
8,665 Added 18.09%
56,575 $5.85 Million
Q3 2023

Oct 23, 2023

BUY
$90.94 - $199.54 $2.24 Million - $4.92 Million
24,655 Added 106.02%
47,910 $4.36 Million
Q2 2023

Aug 07, 2023

BUY
$155.98 - $172.65 $1.72 Million - $1.9 Million
11,005 Added 89.84%
23,255 $3.76 Million
Q1 2023

May 01, 2023

BUY
$132.34 - $159.14 $859,018 - $1.03 Million
6,491 Added 112.71%
12,250 $1.95 Million
Q4 2022

Feb 13, 2023

SELL
$102.55 - $135.33 $61,530 - $81,198
-600 Reduced 9.44%
5,759 $780,000
Q3 2022

Nov 09, 2022

BUY
$95.28 - $116.93 $605,885 - $743,557
6,359 New
6,359 $634,000
Q1 2018

May 11, 2018

SELL
$48.49 - $58.14 $2,424 - $2,907
-50 Closed
0 $0
Q4 2017

Feb 13, 2018

SELL
$47.53 - $53.73 $1.09 Million - $1.23 Million
-22,850 Reduced 99.78%
50 $3,000
Q2 2017

Aug 14, 2017

BUY
N/A
22,900
22,900 $982,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $237B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Compagnie Lombard Odier S Cm A Portfolio

Follow Compagnie Lombard Odier S Cm A and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Compagnie Lombard Odier S Cm A, based on Form 13F filings with the SEC.

News

Stay updated on Compagnie Lombard Odier S Cm A with notifications on news.